Home    Back

Placental mesenchymal stem cells seeded on a commercially available dural graft extracellular matrix    (DrugBank: Placental Mesenchymal Stem Cells)

1 disease
IDDisease name (Link within this page)Number of trials
118Myelomeningocele1

118. Myelomeningocele    [ 9 clinical trials,   15 drugs,   (DrugBank: 7 drugs),   8 drug target genes,   11 drug target pathways]
Searched query = "Myelomeningocele", "Myeloschisis", "Myelocele", "Myelocystocele", "Syringomyelocele"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 9 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04652908
(ClinicalTrials.gov)		February 202125/11/2020Cellular Therapy for In Utero Repair of Myelomeningocele - The CuRe TrialPhase 1/2a Trial of Placental Mesenchymal Stem Cells for Repair of Fetal MyelomeningoceleMyelomeningoceleBiological: Placental Mesenchymal Stem Cells seeded on a commercially available dural graft extracellular matrixDiana Lee FarmerCalifornia Institute for Regenerative Medicine (CIRM)Not yet recruiting19 Weeks25 WeeksAll35Phase 1;Phase 2NULL